77 related articles for article (PubMed ID: 18930588)
1. International agreement to join forces in synthesizing evidence on new methods for cervical cancer prevention.
Arbyn M; Cuzick J
Cancer Lett; 2009 Jun; 278(1):1-2. PubMed ID: 18930588
[TBL] [Abstract][Full Text] [Related]
2. Recommendations for cervical cancer prevention in Asia Pacific.
Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal.
Sankaranarayanan R; Bhatla N; Gravitt PE; Basu P; Esmy PO; Ashrafunnessa KS; Ariyaratne Y; Shah A; Nene BM
Vaccine; 2008 Aug; 26 Suppl 12():M43-52. PubMed ID: 18945413
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus infection and cervical cancer prevention in Japan and Korea.
Konno R; Shin HR; Kim YT; Song YS; Sasagawa T; Inoue M; Park JS
Vaccine; 2008 Aug; 26 Suppl 12():M30-42. PubMed ID: 18945412
[TBL] [Abstract][Full Text] [Related]
5. Integrating human papillomavirus vaccination in cervical cancer control programmes.
Franco EL; Coutlée F; Ferenczy A
Public Health Genomics; 2009; 12(5-6):352-61. PubMed ID: 19684447
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan.
Tay SK; Ngan HY; Chu TY; Cheung AN; Tay EH
Vaccine; 2008 Aug; 26 Suppl 12():M60-70. PubMed ID: 18945415
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention of cervical cancer.
Sasieni P
Best Pract Res Clin Obstet Gynaecol; 2006 Apr; 20(2):295-305. PubMed ID: 16386963
[TBL] [Abstract][Full Text] [Related]
8. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.
Arbyn M; Benoy I; Simoens C; Bogers J; Beutels P; Depuydt C
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):321-30. PubMed ID: 19124515
[TBL] [Abstract][Full Text] [Related]
9. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
Brown DR; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Tay EH; Garcia P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Sings HL; James M; Hesley TM; Barr E
J Infect Dis; 2009 Apr; 199(7):926-35. PubMed ID: 19236279
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of high-risk human papillomavirus type 16/18 infection among women with normal cytology: risk factor analysis and implications for screening and prophylaxis.
Gupta S; Sodhani P; Sharma A; Sharma JK; Halder K; Charchra KL; Sardana S; Singh V; Sehgal A; Das BC
Cytopathology; 2009 Aug; 20(4):249-55. PubMed ID: 19018810
[TBL] [Abstract][Full Text] [Related]
11. Potential role of human papillomavirus in the development of subsequent primary in situ and invasive cancers among cervical cancer survivors.
Balamurugan A; Ahmed F; Saraiya M; Kosary C; Schwenn M; Cokkinides V; Flowers L; Pollack LA
Cancer; 2008 Nov; 113(10 Suppl):2919-25. PubMed ID: 18980275
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention.
Garland SM; Brotherton JM; Skinner SR; Pitts M; Saville M; Mola G; Jones RW
Vaccine; 2008 Aug; 26 Suppl 12():M80-8. PubMed ID: 18945417
[TBL] [Abstract][Full Text] [Related]
13. Cervical cancer screening in the early post vaccine era.
Waxman AG
Obstet Gynecol Clin North Am; 2008 Dec; 35(4):537-48; vii. PubMed ID: 19061815
[TBL] [Abstract][Full Text] [Related]
14. Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer.
Wheeler CM
Obstet Gynecol Clin North Am; 2008 Dec; 35(4):519-36; vii. PubMed ID: 19061814
[TBL] [Abstract][Full Text] [Related]
15. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
Schwarz TF
Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
[TBL] [Abstract][Full Text] [Related]
16. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1.
Jordan J; Arbyn M; Martin-Hirsch P; Schenck U; Baldauf JJ; Da Silva D; Anttila A; Nieminen P; Prendiville W
Cytopathology; 2008 Dec; 19(6):342-54. PubMed ID: 19040546
[TBL] [Abstract][Full Text] [Related]
17. Recommendations for cervical cancer prevention in Latin America and the Caribbean.
Muñoz N; Franco EL; Herrero R; Andrus JK; de Quadros C; Goldie SJ; Bosch FX
Vaccine; 2008 Aug; 26 Suppl 11():L96-L107. PubMed ID: 18945407
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus vaccines and anal carcinoma.
Franceschi S; De Vuyst H
Curr Opin HIV AIDS; 2009 Jan; 4(1):57-63. PubMed ID: 19339940
[TBL] [Abstract][Full Text] [Related]
19. Prevention of cervical cancer: where immunology meets diagnostics.
Meijer CJ; Heideman DA; Berkhof H; Snijders PJ
Immunol Lett; 2009 Feb; 122(2):126-7. PubMed ID: 19100775
[TBL] [Abstract][Full Text] [Related]
20. Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers.
Follen M; Meyskens FL; Alvarez RD; Walker JL; Bell MC; Storthz KA; Sastry J; Roy K; Richards-Kortum R; Cornelison TL
Cancer; 2003 Nov; 98(9 Suppl):2044-51. PubMed ID: 14603541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
